-
Availability of drugs for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis in the World Health Organization European Region, October 2023
-
View Affiliations Hide AffiliationsRalf Otto-Knapprotto-knapp dzk-tuberkulose.de
-
View Citation Hide Citation
Citation style for this article: . Availability of drugs for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis in the World Health Organization European Region, October 2023. Euro Surveill. 2024;29(17):pii=2400211. https://doi.org/10.2807/1560-7917.ES.2024.29.17.2400211 Received: 05 Apr 2024; Accepted: 24 Apr 2024
Abstract
The BPaLM regimen (bedaquiline, pretomanid, linezolid and moxifloxacin) recently recommended by the World Health Organization offers short, safe, and effective treatment for multidrug-resistant/rifampicin-resistant tuberculosis (TB). In a survey with national TB focal points in 18 central and western European countries to explore barriers for the implementation of BPaLM, only three reported full availability of pretomanid, a necessary component of this regimen. Implementation barriers included financing and procurement. Solutions on national and supranational level are needed to guarantee universal access.
Full text loading...